From USFDA
Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration for its ANDA for Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product Vimpat Tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB Inc.Lacosamide Tablets are indicated as adjunctive therapy in patients with partial onset seizures.
Powered by Capital Market - Live News